Notably, the tumor weights by combined administration of HBC with NK1R inhibitors (SR 140333 and aprepitant, respectively) were 4.4 ± 1.6 and 4.2 ± 0.9 mg, respectively, indicating that the combination treatment remarkably suppressed the U87MG GSC-derived tumor growth in comparison with the single-agent treatments. The gene discussed is TACR1; the disease is neoplasm.